Wells Fargo’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $510 | Hold |
2,480
| – | – | ﹤0.01% | 6395 |
|
|
2025
Q4 | $3.92K | Buy |
2,480
+1,070
| +76% | +$1.71K | ﹤0.01% | 6147 |
|
|
2025
Q3 | $1.5K | Sell |
1,410
-176
| -11% | -$304 | ﹤0.01% | 6223 |
|
|
2025
Q2 | $2.54K | Sell |
1,586
-8,395
| -84% | -$13.4K | ﹤0.01% | 6186 |
|
|
2025
Q1 | $12.2K | Buy |
9,981
+659
| +7% | +$1.16K | ﹤0.01% | 5849 |
|
|
2024
Q4 | $17.6K | Buy |
9,322
+3,752
| +67% | +$15.4K | ﹤0.01% | 5797 |
|
|
2024
Q3 | $29.7K | Buy |
5,570
+2,674
| +92% | +$19.6K | ﹤0.01% | 5526 |
|
|
2024
Q2 | $21.4K | Buy |
2,896
+551
| +23% | +$4.42K | ﹤0.01% | 5568 |
|
|
2024
Q1 | $28K | Buy |
2,345
+319
| +16% | +$2.58K | ﹤0.01% | 5472 |
|
|
2023
Q4 | $16K | Buy |
2,026
+484
| +31% | +$4.09K | ﹤0.01% | 5715 |
|
|
2023
Q3 | $6.82K | Sell |
1,542
-8,620
| -85% | -$191K | ﹤0.01% | 5897 |
|
|
2023
Q2 | $354K | Buy |
10,162
+1,742
| +21% | +$47.5K | ﹤0.01% | 4204 |
|
|
2023
Q1 | $184K | Buy |
8,420
+1,483
| +21% | +$33.2K | ﹤0.01% | 4483 |
|
|
2022
Q4 | $150K | Sell |
6,937
-104
| -1% | -$2.26K | ﹤0.01% | 4330 |
|
|
2022
Q3 | $172K | Buy |
7,041
+639
| +10% | +$14.9K | ﹤0.01% | 4327 |
|
|
2022
Q2 | $130K | Buy |
6,402
+1,556
| +32% | +$44.7K | ﹤0.01% | 4494 |
|
|
2022
Q1 | $173K | Buy |
4,846
+938
| +24% | +$29.3K | ﹤0.01% | 5062 |
|
|
2021
Q4 | $107K | Buy |
3,908
+3,556
| +1,010% | +$127K | ﹤0.01% | 5591 |
|
|
2021
Q3 | $15K | Buy |
352
+350
| +17,500% | +$16.9K | ﹤0.01% | 6070 |
|
|
2021
Q2 | $0 | Sell |
2
-29
| -94% | -$1.34K | ﹤0.01% | 7287 |
|
|
2021
Q1 | $1K | Buy |
31
+11
| +55% | +$421 | ﹤0.01% | 6750 |
|
|
2020
Q4 | $0 | Buy |
20
+3
| +18% | +$63 | ﹤0.01% | 6856 |
|
|
2020
Q3 | $0 | Buy |
17
+6
| +55% | +$134 | ﹤0.01% | 6728 |
|
|
2020
Q2 | $0 | Buy |
11
+4
| +57% | +$71 | ﹤0.01% | 6667 |
|
|
2020
Q1 | $0 | Buy |
+7
| New | +$116 | ﹤0.01% | 6622 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | – | – | 6474 |
|
|
2017
Q3 | $0 | Sell |
1
-62
| -98% | -$11.3K | ﹤0.01% | 6421 |
|
|
2017
Q2 | $10K | Buy |
63
+62
| +6,200% | +$17.5K | ﹤0.01% | 5779 |
|
|
2017
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 6440 |
|
|
2016
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 6392 |
|
|
2016
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6302 |
|
|
2016
Q2 | $0 | Buy |
+1
| New | +$596 | ﹤0.01% | 6260 |
|
Other funds holding OTLK
AC
VCM
GWM
WAM
NMC
CCM
Wells Fargo's OTLK Position: Q1 2026 in Review
Wells Fargo held its Outlook Therapeutics (OTLK) position steady in Q1 2026 at 2,480 shares worth $510. The position accounts for ﹤0.01% of the portfolio, ranked #6395.
Wells Fargo first reported a position in OTLK in Q2 2016 and has held it in 31 quarters since. The position peaked at $354K in Q2 2023. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.
- Wells Fargo held 2,480 shares of Outlook Therapeutics worth $510 as of Q1 2026.
- Wells Fargo left its Outlook Therapeutics share count unchanged in Q1 2026.
- Outlook Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6395 holding.
- Wells Fargo first reported a position in Outlook Therapeutics in Q2 2016 and has held it in 31 quarters since.
- Wells Fargo's Outlook Therapeutics position peaked at $354K in Q2 2023.
- 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.